Researchers have developed a novel class of engineered cytokine agonists called Trikines to overcome the limitations of natural immune signaling. By compelling the assembly of three-chain receptor complexes, these molecules allow scientists to customize cellular responses by activating specific combinations of STAT transcription factors. This "mix-and-match" strategy creates bespoke signaling outputs that can promote beneficial immune traits, such as T cell stemness and survival, without the systemic toxicity often associated with traditional cytokine therapies. Pre-clinical models demonstrate that IL-2-based Trikines effectively control tumors while sparing the lungs and liver from inflammation, while IL-10-based Trikines can stimulate immune infiltration into resistant cancers. Ultimately, this modular platform offers a way to reprogram immune cells for better therapeutic outcomes without requiring complex genetic modification.

References:

• Rodriguez G E, Zhao Y, Nishiga Y, et al. Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics[J]. Science, 2026: eadx9954.